Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI

Cancer Statistics, 2010

Ahmedin Jemal, Rebecca L. Siegel, Jiaquan Xu et al. · CA A Cancer Journal for Clinicians · 2010 · 12.6K citations · Full text

Medicine, Oncology, Cancer Epidemiology +16

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with <i>EGFR</i> -Mutant Lung Cancers

Helena A. Yu, Maria E. Arcila, Natasha Rekhtman et al. · Clinical Cancer Research · 2013 · 2.5K citations · Full text

Medicine, Oncology, Pharmacology +17

Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening

Piyush B. Gupta, Tamer T. Önder, Guozhi Jiang et al. · Cell · 2009 · 2.4K citations · Full text

Pharmacy, Medicinal Chemistry, Oncology +14

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

Pasi A. Jänne, James Chih‐Hsin Yang, Dong‐Wan Kim et al. · New England Journal of Medicine · 2015 · 2.1K citations · Full text

Medicine, Oncology, Pharmacology +16

Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance

Kari Fischer, Anna Durrans, Sharrell Lee et al. · Nature · 2015 · 1.8K citations

Medicine, Cell Biology, Oncology +14